Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 100, Issue 2, Pages E55-E58Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2013.01.020
Keywords
Type 1 diabetes; GLP-1; Incretin modulators; Exenatide; Sitagliptin
Categories
Ask authors/readers for more resources
Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available